乳腺癌骨转移骨相关事件对患者生存期的影响

目的:探讨乳腺癌骨转移骨相关事件(skeletal-related events,SREs)的发生及SREs对患者生存期的影响。方法:选择复旦大学附属中山医院和上海市黄浦区中心医院收治的乳腺癌骨转移患者。将患者分为不伴SREs组和伴SREs组,比较两组患者的基本临床特征、骨转移特征,分析SREs的特点及SREs对乳腺癌骨转移患者的骨转移生存期(BS)和总生存期(OS)的影响。结果:乳腺癌骨转移患者共104例,不伴SREs组和伴SREs组分别为46例、58例。两组间年龄、手术方式、肿瘤组织类型、美国癌症联合会(American Joint Committee on Cancer,AJCC)分期、骨转移间歇期、骨转移部位等差异无统计学意义,骨转移数目差异有统计学意义(P=0.006)。骨相关事件间歇期0~48个月,中位时间为5.5(1.0,20.5)个月。SREs以骨痛最多,占70.6%。不伴SREs组和伴SREs组间BS(HR=1.043,95%CI 0.608~1.790,P=0.878)和OS(HR=0.927,95%CI0.543~1.581,P=0.781)差异无统计学意义。结论:SREs不增加乳腺癌骨转移患者的死亡风险。

Effects of skeletal-related events on survival in breast cancer patients with bone metastases

Objective: To explore the skeletal-related events (SREs) in breast cancer patients with bone metastases and its effectiveness of survival in patients. Methods: One hundred and four breast cancer patients with bone metastases were followed up through the median time of 59.5 months. The patients were divided into 2 groups (with SREs or without SREs). The information on clinical characteristics, bone metastases, SREs, bone survivals (BS) and overall survivals (OS) in 2 groups were compared and analyzed. Results: we identified 46 cases without SREs and 58 cases with SREs. The age, type of surgery, molecular type, stage of AJCC, bone metastasis-free interval (BMFI), bone metastasis sites were compared without significant difference (P>0.05), however, the number of bone metastases was with significant difference (P=0.006). The time of skeletal-related events-free interval (SREFI) was from 0 to 48 months, mean time of 12 months. The most common SRE was bone pain (70.6%). No significant difference was noted in BS [HR: 1.043; 95%CI: 0.608~1.790; P=0.878] and OS [HR: 0.927; 95%CI: 0.543~1.581; P=0.781] between the 2 groups. Conclusion: SREs did not increase the risk of death of breast cancer patients with bone metastases.